Publications by authors named "S R T Veerman"
The European Clozapine Task Force is a group of psychiatrists and pharmacologists practicing in 18 countries under European Medicines Agency (EMA) regulation, who are deeply concerned about the underuse of clozapine in European countries. Although clozapine is the most effective antipsychotic for people with treatment-resistant schizophrenia, a large proportion of them do not have access to this treatment. Concerns about clozapine-induced agranulocytosis and stringent blood monitoring rules are major barriers to clozapine prescribing and use.
View Article and Find Full Text PDFArticle Synopsis
- Limited research exists on cognitive functioning in treatment-resistant schizophrenia (TRS), and current findings on clozapine's effect on cognition are inconsistent, with a particular lack of studies on the CLO/NCLO ratio.
- A systematic review identified 15 studies involving clozapine users, assessing their cognitive abilities through various tests and composite scores, with 11 studies deemed of fair quality.
- A negative relationship was discovered between the CLO/NCLO ratio and certain cognitive abilities like attention and social cognition, while no significant correlations were found for other cognitive domains such as processing speed or working memory.
Background: Currently, guidance on the most effective treatment for patients with clozapine-resistant schizophrenia-spectrum disorders (SSD) is lacking. While augmentation strategies to clozapine with aripiprazole and electroconvulsive therapy (ECT) have been demonstrated to be effective in patients with clozapine-resistant schizophrenia spectrum disorders (CRS), head-to-head comparisons between these addition strategies are unavailable. We therefore aim to examine the feasibility of a larger randomized, single-blind trial comparing the effectiveness, cost-effectiveness, and safety of aripiprazole addition vs.
View Article and Find Full Text PDF